Učitavanje...
Modulation of Trabectedin (ET-743) Hepatobiliary Disposition by Multidrug Resistance-Associated Proteins (Mrps) May Prevent Hepatotoxicity
Trabectedin is a promising anticancer agent, but dose-limiting hepatotoxicity was observed during phase I/II clinical trials. Dexamethasone (DEX) has been shown to significantly reduce trabectedin-mediated hepatotoxicity. The current study was designed to assess the capability of sandwich-cultured p...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2007
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2572823/ https://ncbi.nlm.nih.gov/pubmed/18191164 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.taap.2007.11.020 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|